{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:42:02Z","timestamp":1792172522196,"version":"4.4.0"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82588201"],"award-info":[{"award-number":["82588201"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Lymph node metastasis is crucial for esophageal squamous cell carcinoma (ESCC) malignancy. However, the molecular drivers and related mechanisms of lymph node metastasis in ESCC cells are unclear. In the present study, we found that the tyrosine kinase complex-focal adhesion kinase (FAK)\/Src family kinase (SFK) axis specifically contributes to metabolic reprogramming by inducing the phosphorylation of ATP-citrate synthase (ACLY) Tyr542, Tyr652, and fructose-bisphosphate aldolase A (ALDOA) Tyr174, Tyr302, or Tyr328 sites in both primary and metastatic ESCC cells. Mechanistically, activated ACLY and ALDOA and their metabolites drive a transcriptional program in primary tumors that induces cyclin-dependent kinase 7\/9 (CDK7\/9) complex-mediated expression of DNA replication- and cell proliferation-related molecules. This process functions as an enabler of tumor malignancy. In metastatic tumor cells, metabolic enzymes and their products facilitate the transcriptional activity of Yamanaka factors to induce the activation of downstream plasticity-related molecules, fueling ESCC cell survival within metastatic lymph nodes. FAK\/SFK axis-controlled ACLY and ALDOA tyrosine phosphorylation and downstream transcription factors and effectors in primary and metastatic ESCC cells are strongly associated with poor patient outcomes. We discovered a lead compound, quercetagitrin, that inhibits the phosphorylation of ALDOA at Tyr174, 302, and 328. Moreover, it has been shown to have antitumor effects alone or in combination with FAK\/SFK inhibitors both in vivo and in vitro. The inhibition of tyrosine kinase-regulated metabolic enzyme activities and related signaling networks may be a potential strategy for the treatment and diagnosis of metastatic ESCC.<\/jats:p>","DOI":"10.1038\/s41392-025-02395-5","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T01:02:14Z","timestamp":1756688534000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Focal adhesion kinase\/Src family kinase axis-mediated tyrosine phosphorylation of metabolic enzymes facilitates tumor metastasis"],"prefix":"10.1038","volume":"10","author":[{"given":"Jie","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingnan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1731-938X","authenticated-orcid":false,"given":"Qimin","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"2395_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08764-x","volume":"21","author":"C Niu","year":"2021","unstructured":"Niu, C. et al. Risk factors for esophageal squamous cell carcinoma and its histological precursor lesions in China: a multicenter cross-sectional study. BMC Cancer 21, 1034 (2021).","journal-title":"BMC Cancer"},{"key":"2395_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2022.05.054","volume":"163","author":"E Morgan","year":"2020","unstructured":"Morgan, E. et al. The global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020. Gastroenterology 163, 649\u2013658 (2020).","journal-title":"Gastroenterology"},{"key":"2395_CR3","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/SLA.0000000000003499","volume":"274","author":"Y Kurokawa","year":"2021","unstructured":"Kurokawa, Y. et al. Mapping of lymph node metastasis from esophagogastric junction tumors: a prospective nationwide multicenter study. Ann. Surg. 274, 120\u2013127 (2021).","journal-title":"Ann. Surg."},{"key":"2395_CR4","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/jgh.14915","volume":"35","author":"BH Min","year":"2020","unstructured":"Min, B. H. et al. Nomogram for prediction of lymph node metastasis in patients with superficial esophageal squamous cell carcinoma. J. Gastroenterol. Hepatol. 35, 1009\u20131015 (2020).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"2395_CR5","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1586\/egh.11.33","volume":"5","author":"I Gockel","year":"2011","unstructured":"Gockel, I. et al. Risk of lymph node metastasis in submucosal esophageal cancer: a review surgically resected patients. Expert Rev. Gastroenterol. Hepatol. 5, 371\u2013384 (2011).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"2395_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s00508-012-0310-2","volume":"125","author":"N Wu","year":"2013","unstructured":"Wu, N., Chen, Z., Pang, L., Ma, Q. & Chen, G. Prognostic significance of lymph node characteristics on survival in esophageal squamous cell carcinomas. Wien. Klin. Wochenschr. 125, 26\u201333 (2013).","journal-title":"Wien. Klin. Wochenschr."},{"key":"2395_CR7","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.prp.2017.01.023","volume":"213","author":"H Wang","year":"2017","unstructured":"Wang, H., Deng, F., Liu, Q. & Ma, Y. Prognostic significance of lymph node metastasis in esophageal squamous cell carcinoma. Pathol. Res. Pract. 213, 842\u2013847 (2017).","journal-title":"Pathol. Res. Pract."},{"key":"2395_CR8","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.thorsurg.2022.07.001","volume":"32","author":"PK Hsu","year":"2022","unstructured":"Hsu, P. K., Lee, Y. Y., Chuang, L. C. & Wu, Y. C. Lymph node dissection for esophageal squamous cell carcinoma. Thorac. Surg. Clin. 32, 497\u2013510 (2022).","journal-title":"Thorac. Surg. Clin."},{"key":"2395_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41568-023-00568-4","volume":"23","author":"JD Hebert","year":"2023","unstructured":"Hebert, J. D., Neal, J. W. & Winslow, N. M. Dissecting metastasis using preclinical models and methods. Nat. Rev. Cancer 23, 391\u2013407 (2023).","journal-title":"Nat. Rev. Cancer"},{"key":"2395_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nrc.2016.25","volume":"16","author":"PS Steeg","year":"2016","unstructured":"Steeg, P. S. Targeting metastasis. Nat. Rev. Cancer 16, 201\u2013218 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"2395_CR11","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nrc3677","volume":"14","author":"SA Stacker","year":"2014","unstructured":"Stacker, S. A. et al. Lymphangiogenesis and lymphatic vessel remodeling in cancer. Nat. Rev. Cancer 14, 159\u2013172 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"2395_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","volume":"147","author":"S Valastyan","year":"2011","unstructured":"Valastyan, S. & Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell 147, 275\u2013292 (2011).","journal-title":"Cell"},{"key":"2395_CR13","doi-asserted-by":"publisher","first-page":"10411","DOI":"10.1158\/0008-5472.CAN-10-2591","volume":"70","author":"M Kim","year":"2010","unstructured":"Kim, M. et al. CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res. 70, 10411\u201310421 (2010).","journal-title":"Cancer Res."},{"key":"2395_CR14","doi-asserted-by":"publisher","first-page":"djv155","DOI":"10.1093\/jnci\/djv155","volume":"107","author":"HS Jeong","year":"2015","unstructured":"Jeong, H. S. et al. Investigation of the lack of angiogenesis in the formation of lymph node metastases. J. Natl. Cancer Inst. 107, djv155 (2015).","journal-title":"J. Natl. Cancer Inst."},{"key":"2395_CR15","doi-asserted-by":"publisher","first-page":"4667089","DOI":"10.1155\/2023\/4667089","volume":"2023","author":"H Dong","year":"2023","unstructured":"Dong, H. et al. YB-1 expression is associated with lymph node metastasis and drug resistance to Adriamycin in breast cancer. Dis. Markers 2023, 4667089 (2023).","journal-title":"Dis. Markers"},{"key":"2395_CR16","doi-asserted-by":"publisher","first-page":"4276","DOI":"10.7150\/thno.20999","volume":"7","author":"C Zhang","year":"2017","unstructured":"Zhang, C. et al. Noninvasive imaging of CD206-positive M2 macrophages as an early biomarker for post-chemotherapy tumor relapse and lymph node metastasis. Theranostics 7, 4276\u20134288 (2017).","journal-title":"Theranostics"},{"key":"2395_CR17","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ccell.2024.02.002","volume":"42","author":"H Zheng","year":"2024","unstructured":"Zheng, H. et al. PDGFR\u03b1+ITGA11+ fibroblasts foster early-stage cancer lymphovascular invasion and lymphatic metastasis via ITGA11-SELE interplay. Cancer Cell 42, 682\u2013700 (2024).","journal-title":"Cancer Cell"},{"key":"2395_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-024-00509-w","volume":"8","author":"Q Huang","year":"2024","unstructured":"Huang, Q. et al. Multi-omics analysis reveals NNMT as a master metabolic regulator of metastasis in esophageal squamous cell carcinoma. NPJ Precis Oncol. 8, 24 (2024).","journal-title":"NPJ Precis Oncol."},{"key":"2395_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1493","volume":"13","author":"H Huang","year":"2023","unstructured":"Huang, H. et al. Multi-omics analyses reveal spatial heterogeneity in primary and metastatic oesophageal squamous cell carcinoma. Clin. Transl. Med. 13, e1493 (2023).","journal-title":"Clin. Transl. Med."},{"key":"2395_CR20","doi-asserted-by":"publisher","first-page":"1167289","DOI":"10.3389\/fonc.2023.1167289","volume":"13","author":"W Peng","year":"2023","unstructured":"Peng, W., Qiao, H., Mo, L. & Guo, Y. Progress in the diagnosis of lymph node metastasis in rectal cancer: a review. Front. Oncol. 13, 1167289 (2023).","journal-title":"Front. Oncol."},{"key":"2395_CR21","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.celrep.2014.07.036","volume":"8","author":"K Sharma","year":"2014","unstructured":"Sharma, K. et al. Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser\/Thr-based signaling. Cell Rep. 8, 1583\u20131594 (2014).","journal-title":"Cell Rep."},{"key":"2395_CR22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/0092-8674(80)90327-X","volume":"20","author":"BM Sefton","year":"1980","unstructured":"Sefton, B. M., Hunter, T., Beemon, K. & Eckhart, W. Evidence that the phosphorylation of tyrosine is essential for cellular transformation by Rous sarcoma virus. Cell 20, 807\u2013816 (1980).","journal-title":"Cell"},{"key":"2395_CR23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/nrc2900","volume":"10","author":"W Kolch","year":"2010","unstructured":"Kolch, W. & Pitt, A. Functional proteomics to dissect tyrosine kinase signaling pathways in cancer. Nat. Rev. Cancer 10, 618\u2013629 (2010).","journal-title":"Nat. Rev. Cancer"},{"key":"2395_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cell.2019.09.008","volume":"179","author":"A Lundby","year":"2019","unstructured":"Lundby, A. et al. Oncogenic mutations rewire signaling pathways by switching protein recruitment to phosphotyrosine sites. Cell 179, 543\u2013560 (2019).","journal-title":"Cell"},{"key":"2395_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41556-018-0264-3","volume":"21","author":"Q Zhang","year":"2019","unstructured":"Zhang, Q. et al. ALK phosphorylates SMAD4 on tyrosine to disable TGF-beta tumour suppressor functions. Nat. Cell Biol. 21, 179\u2013189 (2019).","journal-title":"Nat. Cell Biol."},{"key":"2395_CR26","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","volume":"131","author":"K Rikova","year":"2007","unstructured":"Rikova, K. et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190\u20131203 (2007).","journal-title":"Cell"},{"key":"2395_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1039\/C9OB01998G","volume":"18","author":"RA Cerulli","year":"2020","unstructured":"Cerulli, R. A. & Kritzer, J. A. Phosphotyrosine isosteres: past, present and future. Org. Biomol. Chem. 18, 583\u2013605 (2020).","journal-title":"Org. Biomol. Chem."},{"key":"2395_CR28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","volume":"19","author":"AJ Cooper","year":"2022","unstructured":"Cooper, A. J., Sequist, L. V. & Lin, J. J. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat. Rev. Clin. Oncol. 19, 499\u2013514 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2395_CR29","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrc2559","volume":"9","author":"J Zhang","year":"2009","unstructured":"Zhang, J., Yang, P. & Gray, N. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28\u201339 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"2395_CR30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41568-021-00340-6","volume":"21","author":"JC Dawson","year":"2021","unstructured":"Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D. & Frame, M. C. Targeting FAK in anticancer combination therapies. Nat. Rev. Cancer 21, 313\u2013324 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2395_CR31","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/nrc3792","volume":"14","author":"FJ Sulzmaier","year":"2014","unstructured":"Sulzmaier, F. J., Jean, C. & Schlaepfer, D. D. FAK in cancer: mechanistic findings and clinical applications. Nat. Rev. Cancer 14, 598\u2013610 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"2395_CR32","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ceb.2006.08.011","volume":"18","author":"SK Mitra","year":"2006","unstructured":"Mitra, S. K. & Schlaepfer, D. D. Integrin-regulated FAK\/Src signaling in normal and cancer cells. Curr. Opin. Cell Biol. 18, 516\u2013523 (2006).","journal-title":"Curr. Opin. Cell Biol."},{"key":"2395_CR33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/nrclinonc.2009.129","volume":"6","author":"LC Kim","year":"2009","unstructured":"Kim, L. C., Song, L. & Haura, E. B. Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 6, 587\u2013595 (2009).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2395_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001","volume":"146","author":"BY Lee","year":"2015","unstructured":"Lee, B. Y., Timpson, P., Horvath, L. G. & Daly, R. J. FAK signaling in human cancer as a target for therapeutics. Pharm. Ther. 146, 132\u2013149 (2015).","journal-title":"Pharm. Ther."},{"key":"2395_CR35","doi-asserted-by":"publisher","first-page":"101244","DOI":"10.1016\/j.xcrm.2023.101244","volume":"4","author":"N Arang","year":"2023","unstructured":"Arang, N. et al. High-throughput chemogenetic drug screening reveals PKC-RhoA\/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. Cell Rep. Med. 4, 101244 (2023).","journal-title":"Cell Rep. Med."},{"key":"2395_CR36","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/s41423-022-00903-z","volume":"19","author":"J Chen","year":"2022","unstructured":"Chen, J. et al. Tumor-associated macrophage (TAM)-derived CCL22 induces FAK addiction in esophageal squamous cell carcinoma (ESCC). Cell Mol. Immunol. 19, 1054\u20131066 (2022).","journal-title":"Cell Mol. Immunol."},{"key":"2395_CR37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s11427-022-2216-x","volume":"66","author":"J Zhang","year":"2023","unstructured":"Zhang, J. et al. Src heterodimerically activates Lyn or Fyn to serve as targets for the diagnosis and treatment of esophageal squamous cell carcinoma. Sci. China Life Sci. 66, 1245\u20131263 (2023).","journal-title":"Sci. China Life Sci."},{"key":"2395_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrclinonc.2016.60","volume":"14","author":"UE Martinez-Outschoorn","year":"2017","unstructured":"Martinez-Outschoorn, U. E., Peiris-Pag\u00e9s, M., Pestell, R. G., Sotgia, F. & Lisanti, M. P. Cancer metabolism: a therapeutic perspective. Nat. Rev. Clin. Oncol. 14, 11\u201331 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2395_CR39","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41568-024-00670-1","volume":"24","author":"V Mohanty","year":"2024","unstructured":"Mohanty, V. Inferring cancer metabolism from gene-expression data. Nat. Rev. Cancer 24, 230 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2395_CR40","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.ejmech.2018.09.001","volume":"157","author":"C Granchi","year":"2018","unstructured":"Granchi, C. ATP citrate lyase (ACLY) inhibitors: an anti-cancer strategy at the crossroads of glucose and lipid metabolism. Eur. J. Med. Chem. 157, 1276\u20131291 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"2395_CR41","doi-asserted-by":"publisher","first-page":"2287128","DOI":"10.1080\/15384047.2023.2287128","volume":"24","author":"J Zhou","year":"2023","unstructured":"Zhou, J. et al. Aldolase A promotes cervical cancer cell radioresistance by regulating the glycolysis and DNA damage after irradiation. Cancer Biol. Ther. 24, 2287128 (2023).","journal-title":"Cancer Biol. Ther."},{"key":"2395_CR42","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.cmet.2022.08.002","volume":"34","author":"D Guo","year":"2022","unstructured":"Guo, D. et al. Aerobic glycolysis promotes tumor immune evasion by hexokinase 2-mediated phosphorylation of I\u03baB\u03b1. Cell Metab. 34, 1312\u20131324 (2022).","journal-title":"Cell Metab."},{"key":"2395_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44772-8","volume":"15","author":"T Chen","year":"2024","unstructured":"Chen, T. et al. AKT1 phosphorylation of cytoplasmic ME2 induces a metabolic switch to glycolysis for tumorigenesis. Nat. Commun. 15, 686 (2024).","journal-title":"Nat. Commun."},{"key":"2395_CR44","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1016\/j.cell.2025.01.024","volume":"188","author":"JL Schneider","year":"2025","unstructured":"Schneider, J. L. et al. GUK1 activation is a metabolic liability in lung cancer. Cell 188, 1248\u20131264 (2025).","journal-title":"Cell"},{"key":"2395_CR45","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ccell.2022.12.004","volume":"41","author":"Z Liu","year":"2023","unstructured":"Liu, Z. et al. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. Cancer Cell 41, 181\u2013195 (2023).","journal-title":"Cancer Cell"},{"key":"2395_CR46","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1038\/s41422-020-0333-6","volume":"30","author":"Y Cui","year":"2020","unstructured":"Cui, Y. et al. Whole-genome sequencing of 508 patients identifies key molecular features associated with poor prognosis in esophageal squamous cell carcinoma. Cell Res. 30, 902\u2013913 (2020).","journal-title":"Cell Res."},{"key":"2395_CR47","doi-asserted-by":"publisher","first-page":"102504","DOI":"10.1016\/j.sbi.2022.102504","volume":"78","author":"N Li","year":"2023","unstructured":"Li, N., Gao, N. & Zhai, Y. DDK promotes DNA replication initiation: mechanistic and structural insights. Curr. Opin. Struct. Biol. 78, 102504 (2023).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"2395_CR48","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.apsb.2022.08.014","volume":"13","author":"D Zhao","year":"2023","unstructured":"Zhao, D. et al. PAFR\/Stat3 axis maintains the symbiotic ecosystem between tumor and stroma to facilitate tumor malignancy. Acta Pharm. Sin. B 13, 694\u2013708 (2023).","journal-title":"Acta Pharm. Sin. B"},{"key":"2395_CR49","doi-asserted-by":"publisher","first-page":"D33","DOI":"10.1093\/nar\/gky822","volume":"47","author":"H Hu","year":"2019","unstructured":"Hu, H. et al. AnimalTFDB 3.0: a comprehensive resource for annotation and prediction of animal transcription factors. Nucleic Acids Res. 47, D33\u2013D38 (2019).","journal-title":"Nucleic Acids Res."},{"key":"2395_CR50","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nature23306","volume":"548","author":"DR Robinson","year":"2017","unstructured":"Robinson, D. R. et al. Integrative clinical genomics of metastatic cancer. Nature 548, 297\u2013303 (2017).","journal-title":"Nature"},{"key":"2395_CR51","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","volume":"21","author":"I Mart\u00ednez-Reyes","year":"2021","unstructured":"Mart\u00ednez-Reyes, I. & Chandel, N. S. Cancer metabolism: looking forward. Nat. Rev. Cancer 21, 669\u2013680 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"2395_CR52","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova, N. N., Zhu, J. & Thompson, C. B. The hallmarks of cancer metabolism: still emerging. Cell Metab. 34, 355\u2013377 (2022).","journal-title":"Cell Metab."},{"key":"2395_CR53","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.molcel.2018.06.023","volume":"71","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Macrophage-associated PGK1 phosphorylation promotes aerobic glycolysis and tumorigenesis. Mol. Cell 71, 201\u2013215 (2018).","journal-title":"Mol. Cell"},{"key":"2395_CR54","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41556-023-01133-9","volume":"25","author":"K Wu","year":"2023","unstructured":"Wu, K. et al. Creatine kinase B suppresses ferroptosis by phosphorylating GPX4 through a moonlighting function. Nat. Cell Biol. 25, 714\u2013725 (2023).","journal-title":"Nat. Cell Biol."},{"key":"2395_CR55","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.ccell.2019.01.009","volume":"35","author":"X Feng","year":"2019","unstructured":"Feng, X. et al. A platform of synthetic lethal gene interaction networks reveals that the GNAQ uveal melanoma oncogene controls the hippo pathway through FAK. Cancer Cell 35, 457\u2013472 (2019).","journal-title":"Cancer Cell"},{"key":"2395_CR56","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.semcancer.2019.07.021","volume":"60","author":"B Ma","year":"2020","unstructured":"Ma, B., Wells, A. & Clark, A. M. The pan-therapeutic resistance of disseminated tumor cells: role of phenotypic plasticity and the metastatic microenvironment. Semin. Cancer Biol. 60, 138\u2013147 (2020).","journal-title":"Semin. Cancer Biol."},{"key":"2395_CR57","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41571-018-0134-8","volume":"16","author":"RL Anderson","year":"2019","unstructured":"Anderson, R. L. et al. A framework for the development of effective anti-metastatic agents. Nat. Rev. Clin. Oncol. 16, 185\u2013204 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2395_CR58","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s43018-021-00181-0","volume":"2","author":"M Esposito","year":"2021","unstructured":"Esposito, M., Ganesan, S. & Kang, Y. Emerging strategies for treating metastasis. Nat. Cancer 2, 258\u2013270 (2021).","journal-title":"Nat. Cancer"},{"key":"2395_CR59","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/d41573-025-00009-x","volume":"24","author":"MT Villanueva","year":"2025","unstructured":"Villanueva, M. T. Targeting inherited mutations to prevent metastasis. Nat. Rev. Drug Discov. 24, 90 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2395_CR60","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.cell.2024.03.011","volume":"187","author":"T Cao","year":"2024","unstructured":"Cao, T. et al. Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells. Cell 187, 2288\u20132304 (2024).","journal-title":"Cell"},{"key":"2395_CR61","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1016\/j.ccell.2024.10.010","volume":"42","author":"H Lin","year":"2024","unstructured":"Lin, H. et al. Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. Cancer Cell 42, 2032\u20132044 (2024).","journal-title":"Cancer Cell"},{"key":"2395_CR62","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ccell.2022.11.013","volume":"41","author":"H Teng","year":"2023","unstructured":"Teng, H. et al. Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer. Cancer Cell 41, 124\u2013138 (2023).","journal-title":"Cancer Cell"},{"key":"2395_CR63","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.bbcan.2017.07.002","volume":"1868","author":"Y He","year":"2017","unstructured":"He, Y. et al. Nuclear localization of metabolic enzymes in immunity and metastasis. Biochim Biophys. Acta Rev. Cancer 1868, 359\u2013371 (2017).","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"key":"2395_CR64","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/ncb2629","volume":"14","author":"W Yang","year":"2012","unstructured":"Yang, W. et al. ERK1\/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell Biol. 14, 1295\u20131304 (2012).","journal-title":"Nat. Cell Biol."},{"key":"2395_CR65","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41422-022-00628-8","volume":"32","author":"X Lu","year":"2022","unstructured":"Lu, X. et al. EGFR signaling promotes nuclear translocation of plasma membrane protein TSPAN8 to enhance tumor progression via STAT3-mediated transcription. Cell Res. 32, 359\u2013374 (2022).","journal-title":"Cell Res."},{"key":"2395_CR66","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.molcel.2018.03.018","volume":"70","author":"J Lee","year":"2018","unstructured":"Lee, J. et al. EGFR-phosphorylated platelet isoform of phosphofructokinase 1 promotes PI3K activation. Mol. Cell 70, 197\u2013210 (2018).","journal-title":"Mol. Cell"},{"key":"2395_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08921-8","volume":"10","author":"R Liu","year":"2019","unstructured":"Liu, R. et al. Tyrosine phosphorylation activates 6-phosphogluconate dehydrogenase and promotes tumor growth and radiation resistance. Nat. Commun. 10, 991 (2019).","journal-title":"Nat. Commun."},{"key":"2395_CR68","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature13176","volume":"509","author":"Y Song","year":"2014","unstructured":"Song, Y. et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509, 91\u201395 (2014).","journal-title":"Nature"},{"key":"2395_CR69","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.ajhg.2015.02.017","volume":"96","author":"L Zhang","year":"2015","unstructured":"Zhang, L. et al. Genomic analyses reveal mutational signatures and frequently altered genes in esophageal squamous cell carcinoma. Am. J. Hum. Genet. 96, 597\u2013611 (2015).","journal-title":"Am. J. Hum. Genet."},{"key":"2395_CR70","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ajhg.2016.02.021","volume":"98","author":"H Qin","year":"2016","unstructured":"Qin, H. et al. Genomic characterization of esophageal squamous cell carcinoma reveals critical genes underlying tumorigenesis and poor prognosis. Am. J. Hum. Genet. 98, 709\u2013727 (2016).","journal-title":"Am. J. Hum. Genet."},{"key":"2395_CR71","doi-asserted-by":"publisher","first-page":"3930","DOI":"10.7150\/jca.52286","volume":"12","author":"F Ma","year":"2021","unstructured":"Ma, F. et al. Heterogeneity analysis of esophageal squamous cell carcinoma in cell lines, tumor tissues and patient-derived xenografts. J. Cancer 12, 3930\u20133944 (2021).","journal-title":"J. Cancer"},{"key":"2395_CR72","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41568-023-00658-3","volume":"24","author":"S Peuget","year":"2024","unstructured":"Peuget, S., Zhou, X. & Selivanova, G. Translating p53-based therapies for cancer into the clinic. Nat. Rev. Cancer 24, 192\u2013215 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"2395_CR73","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang, H., Guo, M., Wei, H. & Chen, Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct. Target Ther. 8, 92 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2395_CR74","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nrc2715","volume":"9","author":"KH Vousden","year":"2009","unstructured":"Vousden, K. H. & Ryan, K. M. p53 and metabolism. Nat. Rev. Cancer 9, 691\u2013700 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"2395_CR75","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","volume":"22","author":"O Hassin","year":"2023","unstructured":"Hassin, O. & Oren, M. Drugging p53 in cancer: one protein, many targets. Nat. Rev. Drug Discov. 22, 127\u2013144 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2395_CR76","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/cdd.2017.171","volume":"25","author":"AM Kaiser","year":"2018","unstructured":"Kaiser, A. M. & Attardi, L. D. Deconstructing networks of p53-mediated tumor suppression in vivo. Cell Death Differ. 25, 93\u2013103 (2018).","journal-title":"Cell Death Differ."},{"key":"2395_CR77","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nature07943","volume":"458","author":"MR Stratton","year":"2009","unstructured":"Stratton, M. R., Campbell, P. J. & Futreal, P. A. The cancer genome. Nature 458, 719\u2013724 (2009).","journal-title":"Nature"},{"key":"2395_CR78","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","volume":"20","author":"F Mart\u00ednez-Jim\u00e9nez","year":"2020","unstructured":"Mart\u00ednez-Jim\u00e9nez, F. et al. A compendium of mutational cancer driver genes. Nat. Rev. Cancer 20, 555\u2013572 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"2395_CR79","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2159-8290.CD-19-0528","volume":"10","author":"J Chou","year":"2020","unstructured":"Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. & Ashworth, A. Transcription-associated cyclin-dependent kinases as targets and biomarkers for cancer therapy. Cancer Discov. 10, 351\u2013370 (2020).","journal-title":"Cancer Discov."},{"key":"2395_CR80","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.cell.2018.07.045","volume":"175","author":"W Minzel","year":"2018","unstructured":"Minzel, W. et al. Small molecules co-targeting CKI\u03b1 and the transcriptional kinases CDK7\/9 control AML in preclinical models. Cell 175, 171\u2013185 (2018).","journal-title":"Cell"},{"key":"2395_CR81","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-023-01555-9","volume":"8","author":"M Lv","year":"2023","unstructured":"Lv, M. et al. CDK7-YAP-LDHD axis promotes D-lactate elimination and ferroptosis defense to support cancer stem cell-like properties. Signal Transduct. Target Ther. 8, 302 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"2395_CR82","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrc3847","volume":"14","author":"DK Graham","year":"2014","unstructured":"Graham, D. K., DeRyckere, D., Davies, K. D. & Earp, H. S. The TAM family: phosphatidylserine-sensing receptor tyrosine kinase gone awry in cancer. Nat. Rev. Cancer 14, 769\u2013785 (2014).","journal-title":"Nat. Rev. Cancer"},{"key":"2395_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1022-2","volume":"18","author":"KV Myers","year":"2019","unstructured":"Myers, K. V., Amend, S. R. & Pienta, K. J. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment. Mol. Cancer 18, 94 (2019).","journal-title":"Mol. Cancer"},{"key":"2395_CR84","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","volume":"38","author":"M Katoh","year":"2016","unstructured":"Katoh, M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int. J. Mol. Med. 38, 3\u201315 (2016).","journal-title":"Int. J. Mol. Med."},{"key":"2395_CR85","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.cell.2020.08.040","volume":"183","author":"A Sharma","year":"2020","unstructured":"Sharma, A. et al. Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma. Cell 183, 377\u2013394 (2020).","journal-title":"Cell"},{"key":"2395_CR86","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.mehy.2016.02.018","volume":"90","author":"JL Hood","year":"2016","unstructured":"Hood, J. L. Melanoma exosomes enable tumor tolerance in lymph nodes. Med. Hypotheses 90, 11\u201313 (2016).","journal-title":"Med. Hypotheses"},{"key":"2395_CR87","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/nrc3587","volume":"13","author":"GK Alderton","year":"2013","unstructured":"Alderton, G. K. Metastasis: active lymph nodes. Nat. Rev. Cancer 13, 606\u2013607 (2013).","journal-title":"Nat. Rev. Cancer"},{"key":"2395_CR88","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.apsb.2020.07.011","volume":"11","author":"J Chen","year":"2021","unstructured":"Chen, J. et al. Chrysin serves as a novel inhibitor of DGK\u03b1\/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). Acta Pharm. Sin. B 11, 143\u2013155 (2021).","journal-title":"Acta Pharm. Sin. B"},{"key":"2395_CR89","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1002\/mc.23273","volume":"60","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K\/AKT axis and downstream molecular network. Mol. Carcinog. 60, 113\u2013124 (2021).","journal-title":"Mol. Carcinog."},{"key":"2395_CR90","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41392-023-01728-6","volume":"9","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. AKT2S128\/CCT\u03b1S315\/319\/323-positive cancer-associated fibroblasts (CAFs) mediate focal adhesion kinase (FAK) inhibitors resistance via secreting phosphatidylcholines (PCs). Signal Transduct. Target Ther. 9, 21 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"2395_CR91","doi-asserted-by":"publisher","first-page":"101055","DOI":"10.1016\/j.drup.2024.101055","volume":"73","author":"J Chen","year":"2024","unstructured":"Chen, J. et al. Tumor-associated macrophage (TAM)-secreted CCL22 confers cisplatin resistance of esophageal squamous cell carcinoma (ESCC) cells via regulating the activity of diacylglycerol kinase \u03b1 (DGK\u03b1)\/NOX4 axis. Drug Resist. Update 73, 101055 (2024).","journal-title":"Drug Resist. Update"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02395-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02395-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02395-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:23:42Z","timestamp":1756898622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02395-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2395"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02395-5","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"30 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that no competing interests exist. Qimin Zhan is an editorial member of Signal Transduction and Targeted Therapy, but he has not been involved in the process of manuscript handling.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}